Tuesday, November 01, 2022
Cleerly, the company creating a new standard of care for heart disease, announced a new workflow solution to its portfolio, Proxy. Cleerly Proxy is a software that allows Cleerly to seamlessly transmit data to care providers by automating the upload of coronary computed tomography angiography (CCTA) scans from local systems to Cleerly’s cloud service. The pre-hardened virtual machine can be installed and configured in minutes to save time and reduce security risks for each Cleerly heart analysis.
“Proxy is a turnkey solution that gives physicians and providers more time to focus directly on a patient’s heart care while we manage their workflows and provide IT and security comfort,” said Nick Nieslanik, chief technology officer at Cleerly. “By removing the need for multiple systems and workflows, heart disease detection becomes the priority and lets us drive the necessary reporting and analytics insights to the various stakeholders quickly, meeting them right where they need.”
A single Cleerly Proxy installation can be used as an endpoint to receive CCTA scans from one or more imaging modality, picture archiving and communication system (PACS) or vendor neutral archive (VNA) modalities. Each scan can then be uploaded into the Cleerly service for one or more providers to review and share results with patients.
Cleerly Proxy is distributed as an OVA file along with a site-specific configuration. The virtual appliance can typically be imported and launched in as little as five minutes. As a part of the set-up, Cleerly’s implementation specialists remotely assist partners through the deployment, configuration and end-to-end testing of their first digital imaging and communications medicine (DICOM) uploads and optional PACS report delivery.
“With Proxy, our goal is to be completely seamless and allow providers to better treat their heart patients,” said James Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “The addition of Proxy to our portfolio will decrease the time in which providers receive our AI-based quantifiable disease analysis with a tool that fits directly into their workflows. This virtual appliance is another way we are improving how heart disease is identified, prevented and treated.”